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Introduction: Interferon gamma (IFNγ) is the most potent cytokine involved in the control of 
Mycobacterium tuberculosis (Mtb), the etiological agent of human tuberculosis (TB). Patients with 
active TB present reduced levels of IFNγ, which may explain the lack of effective immunity against 
Mtb in these patients. The diminished expression of or functional alterations in trans-acting factors that 
regulate IFNγ gene expression may explain the reduced levels of IFNγ in TB patients.
Objective: To investigate the relationships of genetic variants in the transcription factors TBET, STAT1, 
STAT4, and HLX to susceptibility/resistance to pulmonary TB.
Materials and methods: Eight candidate single-nucleotide polymorphisms (SNPs) were selected, and 
genotyped in 466 unrelated pulmonary TB patients and 300 healthy controls from Colombia, and the 
allelic and genetic associations with TB were analyzed. 
Results: The results indicate that no SNP in the transcription factors studied is associated with TB. 
However, polymorphism rs11650354 in the TBET gene may be associated with a decreased risk of 
TB; the TT genotype was significantly associated with TB protection in a recessive genetic model 
(OR=0.089, 95% CI: 0.01-0.73, p=0.0069), although this association was not maintained after multiple 
test correction (EMP2= 0.61).
Conclusion: In this study, the rs11650354 variant of TBET was suggested to promote resistance to 
TB in a Colombian population. A future replication case-control study using additional samples will be 
necessary to confirm this suggestive association. 
Keywords: Mycobacterium tuberculosis, interferon gamma, transcription factor, STAT1, STAT4, case-
control studies.
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Variantes en los factores de transcripción para IFNγ, TBET, STAT1, STAT4 y HLX, y el riesgo 
de desarrollar tuberculosis pulmonar en un estudio de casos y controles de una población 
colombiana
Introducción. El interferón gama (IFNγ) es la citocina más potente para controlar la infección por 
Mycobacterium tuberculosis, el agente etiológico de la tuberculosis humana. Los pacientes con 
tuberculosis activa presentan reducción de los niveles de IFNγ, lo cual parece explicar la inmunidad 
poco efectiva contra el bacilo. La disminución de su expresión o alteraciones funcionales de los factores 
transactivadores del promotor del gen de IFNγ, podrían explicar la reducción de los niveles de IFNγ en 
los pacientes con tuberculosis.
Objetivo. Determinar la asociación de variantes genéticas en los factores de transcripción TBET, 
STAT1, STAT4 y HLX con sensibilidad o resistencia a tuberculosis pulmonar.
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Materiales y métodos. Se seleccionaron ocho polimorfismos de un solo nucleótido (Single-Nucleotide 
Polymorphism, SNP) y se estableció su genotipo, en 466 pacientes con tuberculosis pulmonar y 300 
controles sanos en Colombia; además, se hizo un análisis de asociación alélica y genética.
Resultados. Los resultados indican que los SNP de los factores de transcripción estudiados no están 
asociados con tuberculosis; sin embargo, el polimorfismo rs11650354 en TBET puede estar implicado 
en la disminución de riesgo de tuberculosis. El genotipo TT de TBET se asoció significativamente 
con protección contra tuberculosis usando un modelo genético recesivo (OR=0,089; CI95%: 0,01-0,73; 
p=0,0069); sin embargo, la corrección mediante pruebas múltiples de ajuste abolió esta asociación 
(Empirical P Value, EMP2=0,61).
Conclusión. En este estudio se sugiere un efecto de la variante rs11650354 de TBET sobre la 
resistencia a la tuberculosis en la población colombiana. Es necesario desarrollar un estudio de 
replicación usando muestras adicionales para confirmar esta asociación sugestiva.
Palabras clave: Mycobacterium tuberculosis, interferón-gamma, factor de transcripción STAT1, factor 
de transcripción STAT4, estudios de casos y controles.
doi: http://dx.doi.org/10.7705/biomedica.v33i2.790
It is estimated that one-third of the human population 
is infected with Mycobacterium tuberculosis (Mtb), 
the etiological agent of tuberculosis (TB). TB is a 
complex disease, and its occurrence is influenced 
by environmental, immunologic and genetic factors. 
It is estimated that 10% of Mtb-infected individuals 
may develop active TB during their lifetimes 
(1), suggesting that the majority of the infected 
individuals are endowed with a protective immune 
response.
IFNγ is a potent cytokine with pleiotropic activities 
in different cell types, and it is considered the major 
activator of macrophages, a cell type that is critical 
to the control of Mtb replication and dissemination. 
In addition, IFNγ acts on professional antigen 
presenting cells, increasing MHC class II expression 
and thus favoring the adaptive T cell response. IFNγ 
is produced by different cell populations, including 
Natural Killer (NK) cells (2), T lymphocytes (LT) αβ 
(CD4+ and CD8+ T cells), LTγδ cells (3), dendritic 
cells (DCs) (4), and monocytes/macrophages (5).
IFNγ activity is crucial for mycobacterial control in 
Mtb-infected cells. It stimulates the production of 
inducible nitric oxide synthase (NOS-2), which is 
known to be responsible for high levels of nitric 
oxide, and other reactive nitrogen intermediates 
that are bactericidal to Mtb in mice (6), although the 
role of NOS-2 in human TB remains controversial. 
IFNγ also induces the expression of LRG-47, a 
p47 GTPase that controls Mtb by allowing the 
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autophagy of infected macrophages (7). The 
importance of IFNγ during Mtb infection has been 
demonstrated in both mice and humans. Mice that 
are deficient in IFNγ or the IFNγ receptor (IFNγR) 
rapidly succumb to infection with Mtb or M. bovis 
BCG (8,9). Individuals with mutations in the 
IFNGR1 or IFNGR2 genes (encoding the IFNγ-R1 
and R2 receptors, respectively) or IFNγ-intracellular 
pathway components such as the STAT1 protein 
may experience fatal disseminated BCG or 
non-tuberculous mycobacterial infection during 
childhood (10). Polymorphic variants in the IFNG 
and IFNG receptor genes have been associated 
with variable levels of IFNγ production (11,12).
Different reports indicate that peripheral blood 
mononuclear cells (PBMCs) from patients with 
severe active TB produce lower levels of IFNγ 
protein and mRNA in response to mycobacterial 
antigens than do healthy tuberculin reactor subjects 
(13,14) or with household healthy contacts of 
TB patients (15). This impaired IFNγ production 
could be associated with an inability to clear the 
bacterial load and the consequent progress of 
the disease and its pathology. This assumption 
is consistent with evidence suggesting that IFNγ 
expression correlates with protective immunity 
against TB (6,8,9); however, according to other 
studies, high levels of IFNγ protein post-infection 
represents a risk factor for developing active TB 
(16-20). These data suggest that the mechanisms 
that control the excessive inflammatory responses 
during Mtb infection may have a critical role in the 
immunopathology of TB.
The molecular regulation of IFNγ is a complex 
process because multiple signals converge to 
govern its expression (21,22). Different regulatory 
regions of the IFNγ locus have been identified, and 
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multiple transcription factors have been implicated 
in the regulation of IFNγ gene expression (23). 
Transcription factors such as TBET (T-box 21) 
(24), GATA3 (25), STAT1 (Signal Transducers and 
Activators of Transcription 1) (26), STAT4 (27), 
HLX (H2.0-like homeobox) (28), CREB (29), ATF-2, 
c-Jun (30), and NF-κB (22) have been implicated in 
the regulation of IFNγ gene expression. Few studies 
have tested whether the reduced IFNγ mRNA and 
protein production in human TB is due to functional 
mutations in any of these transcription factors. 
Reduced CREB protein expression or the absence 
of phosphorylated nuclear CREB in TB patients 
resulted in decreased IFNγ promoter activity 
and reduced IFNγ production (29). However, it is 
presently unknown whether genetic variants of this 
and other transcription factors may be associated 
with susceptibility/resistance to TB. 
IFNγ plays a critical role during Mtb infection, 
and there is evidence indicating the crucial role 
of regulation of IFNγ production. Therefore, we 
performed a case-control gene association study 
in a Colombian population of pulmonary TB cases 
and healthy controls, using transcription factors 
that positively or negatively regulate IFNG gene 
expression as the candidate associated genes. 
A trend for association with a decreased risk 
for TB (OR±95%CI=0.089±0.01-0.73; χ2=7.99; 
p=0.0069) was found for the TT genotype of TBET 
(rs11650354 SNP) assuming a recessive model 
of inheritance; however, this significance was 
lost after multiple test correction via permutation 
(EMP=0.61). The populations were also genotyped 
for additional single nucleotide polymorphisms 
in the STAT1, STAT4, and HLX genes; however, 
none of these SNPs was found to be associated 
with susceptibility/resistance to TB.
Materials and methods
Subjects
Pulmonary TB patients (n=499) and healthy controls 
(n=320) of Mestizo ethnicity were recruited from the 
metropolitan area of Medellín, the capital city of the 
Antioquia Department, Colombia. The incidence 
of tuberculosis in Colombia was last reported as 
34 per 100,000 inhabitants in 2010, according 
to a World Bank report released in 2011 (31). In 
Medellin, the records of the incidence of TB show 
rates ranging from 40.4 to 60.7 cases per 100,000 
inhabitants (32). The cases included in this study 
were newly diagnosed TB patients with disease 
confirmed by sputum smear examinations for acid-
fast bacilli and/or culture for Mtb. The cases were 
enrolled from February 2002 to September 2004 
(from a cross-sectional study; n=119) and from 
March 2005 to November 2006 (from a cohort 
study (20); n=380). The control subjects were 
healthy (as defined by Interferon Gamma Release 
Assays, IGRA), non-related household contacts, 
enrolled (collected from March 2005 to December 
2006; n=105), and non-contact individuals living in 
the same neighborhood as the TB patients (source 
population), randomly sampled and age-matched to 
the TB patients (n=215), enrolled from September 
2007 to December 2008. The exclusion criteria 
for patients included positive serologic tests for 
Human Immunodeficiency Virus (HIV), a history of 
organ transplantation, primary immunodeficiency, 
cancer, treatment with immunosuppressive drugs, 
endocrine disorders such as diabetes, autoimmune 
and chronic renal disease, or the development of 
pleural, miliary or meningeal TB. The exclusion 
criteria for controls included persistent productive 
cough (for more than 2 weeks) and a previous 
history of TB. No household contact participating in 
this study showed clinical symptoms of TB during the 
2 years of clinical follow-up. All subjects signed an 
informed consent document that was approved by 
the Ethics Committee of the Facultad de Medicina, 
Universidad de Antioquia. Table 1 shows the 
demographic characteristics of the 466 TB patients 
and 300 healthy controls that were included in the 
association analyses. Samples from 33 TB patients 
and 20 healthy controls were eliminated during the 
genotype quality control analyses, as described 
below. 
Blood samples and DNA isolation
Venous blood samples (3-8 ml in EDTA; BD 
Vacutainers) were collected. Genomic DNA was 
extracted using the DNAzol reagent (ES Extra 
Strength MCR, Cincinnati, OH, USA) according 
to the manufacturer’s instructions. The isolated 
DNA was suspended in TE 1X (pH 7.9) and stored 
at 4°C. DNA integrity was visualized by ethidium 
bromide staining of 0.7% agarose (Amresco; Solon, 
OH, USA) gels. DNA samples were quantified 
using the Quant-iT PicoGreen dsDNA reagent 
(Invitrogen Molecular Probes, Eugene, OR, USA) 
as recommended by the manufacturer.
SNP selection and genotyping
Eight SNPs in the TBET, HLX, GATA3, STAT1, 
and STAT4 genes were evaluated. The SNPs 
were strategically selected according to their 
locations in areas of potential importance for gene 
regulation or protein function and/or regions that 
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are in LD with other SNPs previously reported to 
be associated with different diseases. The SNPs 
rs11578466 and rs11588625 in the HLX gene were 
used as proxies for an HLX SNP that lies within the 
3’ untranslated region (HLX1-C/T, 3’ UTR; NCBI 
dbSNP: rs2738756). SNP genotype information for 
the CEU population was downloaded from HapMap 
database (phase II release 21a from January 
2007). Primer design software (MassARRAY Assay 
Design) was used to design PCR and hME primers 
for the high-plexed MassEXTEND (hME) assays 
to avoid overlapping mass signals in the available 
spectrum range for each target SNP. Samples 
were genotyped at the Laboratory for Genetics and 
Genomic Medicine of Inflammation (http://www.
inflammgen.org), Université de Montreal, Montreal, 
Canada, by MassARRAY (Sequenom, San Diego, 
CA, USA); this technique uses chip-based Matrix 
Assisted Laser Desorption/Ionization Time-of-Flight 
(MALDI-TOF) mass spectrometry, as previously 
described (33).
Data processing 
To optimize the quality of the data (quality control, 
QC) while keeping as many SNPs and samples 
as possible, we selected different parameter 
thresholds using PLINK v1.04 (34). The PLINK 
QC options were set to the following thresholds: 
maximum missing genotypes per person (--mind 
option) ≤0.20, maximum missing genotypes per 
SNP (--geno option) ≤0.10 and Hardy–Weinberg 
Equilibrium (HWE; exact) P-value <0.05 in controls 
(--hwe option). These QC steps produced a final 
high-quality dataset with an average call rate of 
more than 80% per individual and per SNP. Of the 
initial DNA samples from 499 TB patients and 320 
controls, 33 samples from TB patients and 20 from 
healthy controls were removed due to low genotype 
call rates. The final post-QC analysis dataset 
yielded an average genotype call rate of 98.1%. 
Statistical analysis
Association testing was performed with PLINK software 
v1.04. A single marker basic allelic association test 
(--assoc --Fisher option) and genotypic association 
test (--model --Fisher option) were performed for 
each of the post-QC SNPs. To test for the mode of 
inheritance, 2×3 tables, Fisher’s exact test and ORs 
with 95% confidence intervals (CI) were calculated. 
For SNPs that showed a significant genotypic 
association (p<0.05), a PLINK’s max(T) permutation 
procedure (--mperm option) with 100,000 iterations 
was performed to limit type II error. PLINK generates 
both uncorrected (EMP1) and corrected (EMP2) 
empirical P-values. In both cases, p-values of <0.05 
were considered significant. 
The Mann-Whitney statistical test was used for age 
comparisons, and the χ2 test was used to test for 
gender differences between cases and controls. 
To adjust for potential confounding, gender was 
included in a forward stepwise logistic regression 
analysis for SNPs with significant genotypic 
association using the Statistical Package for 
the Social Sciences (SPSS v.11.5 for Windows; 
Chicago, IL). Statistically significant associations 
were defined by a p≤0.05.
Results
The demographic and clinical characteristics of the 
population analyzed in our study are shown in Table 
1. Of the initial 499 TB patients and 320 controls, the 
DNA samples from 33 TB patients and 20 healthy 
controls were removed from the analysis due to low 
genotype call rates. There was no difference in age 
distribution between cases and controls (p=0.46), 
but men were more frequent in the TB patient group 
than in the control group (p<0.001). Two SNPs 
in GATA3 (rs4143094 and rs1058240) showed 
deviations from Hardy-Weinberg Equilibrium (HWE) 
in the control group and were removed for further 
Table 1. Demographic and clinical characteristics of the study population
Demographic TB patients (466)a Healthy controls (300)a P value
characteristic Cohort Cross-sectional Household Source
 study study  contacts population
 (350) (116) (96) (204) 
Female  155 58 56 120 <0.001b
Male 195 58 40 84   <0.001b
Median agec 39 (26-51) 42 (25-54) 0.46d
aA total of 499 TB patients and 320 controls were enrolled in the study, but 33 samples from patients with TB and 20 from healthy 
controls were removed for low genotype call rates. The final data set post-quality control analyses gave an average genotype call 
rate of 98.1%. bPearson’s chi-square comparing sex between TB and healthy controls. cYears (interquartile range); dMann-Whitney 
statistical test comparing TB patients with healthy controls.
Abbreviation: TB, tuberculosis
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analysis. The remaining 8 SNPs tested passed 
QC analysis (genotyping success <80%) and were 
included in the subsequent analyses. 
The results of the allelic association analyses did 
not reveal any differences in the frequencies of 
TBET, HLX, STAT1, and STAT4 polymorphisms 
between TB cases and controls (table 2). Genotype 
frequency analysis was also performed (table 3), 
and a significant difference between TB patients and 
controls was found in TBET rs11650354 SNP, with 
genotypic frequencies significantly decreased in 
cases compared with controls (χ2=8.06; P=0.019).
To analyze the genotypic effect, we performed a 
comparison of genotypic models in which the risk 
allele was dominant or recessive. The frequency 
of the TT genotype of TBET (recessive model of 
inheritance) was significantly lower in TB patients 
(OR±95%CI= 0.089±0.01-0.73; χ2=7.99; p=0.0069) 
than in controls. This difference persisted even after 
adjusting for the gender distribution between groups 
(p=0.02), as shown using a logistic regression analysis 
controlling for gender as a covariate. Genotypic 
significance was ascertained through a permutation 
of phenotypes (n=100,000 permutations) over all 
81 SNPs (the total number of SNPs included in the 
complete genetic study using the same Colombian 
samples ((35) and unpublished data) in the analysis. 
After these stringently corrected permuted p-values 
were applied, the rs11650354 SNP did not remain 
significantly associated with TB protection (EMP2 
p=0.61; table 3).
Discussion
Studies in the genetics of TB resistance/susceptibility 
have identified several important candidate genes 
(discussed in (36)) and genetic regions (37). IFNγ 
has been identified as a key cytokine in the control 
of mycobacterial infections, as clearly demonstrated 
in mice models of infection (38,39) as well as in 
human genetic studies evaluating polymorphisms 
in the IFNG gene (40-42) and other genes involved 
in the modulation of IFNγ production or signaling 
(43,44).
Under the hypothesis that IFNγ production is critical 
for the successful control of Mtb infection and 
multiplication, we studied SNPs from five specific 
Table 3. TBET genotype frequencies and inheritance model analysis 
 Number of individuals  χ2      p-valuea Recessive mode of inheritance
 in each genotype (%) (2 d.f.)   
Gene SNP ID Status CC CT TT χ2       p valueb OR          (95% CI) EMP1 EMP2
    n  n  n (1 d.f.) (adjusted
    (%) (%) (%)    p value)c  
    376 89         
  TB cases (80.7) (19.1) 1 (0.2) 8.06 0.019 7.99  0.0069  0.089  0.011 0.61
TBET rs11650354 Healthy  233 58      (0.02) (0.01-0.73)    
  controls (78.2) (19.5) 7 (2.3) 
a Fisher’s exact test for 3×2 comparisons of genotypes in the different populations
 b Fisher’s exact test for 2×2 comparisons of genotypes in the recessive model of inheritance (TT vs CC+CT) between groups
c Logistic regression for confounding factors in the gender phenotype. The Hosmer-Lemeshow goodness of fit tests indicated no significance (p>0.05). 
Correction for the effects of gender using logistic regression did not affect the observed associations for TBET.
The results of the permutation testing are displayed as uncorrected P-values (EMP1) and permuted P-values corrected for the number of tests 
performed (EMP2). 
Abbreviations: SNP ID, single nucleotide polymorphism database identification number; OR, odds ratio; CI, confidence interval; d.f., degrees of 
freedom
Table 2. Allele frequencies
SNP ID Gene Chr SNP Alleles MAF in MAF P valuea
   position (A1/A2) cases in Controls 
rs3771300 STAT1 2q32.2 Intron C/A 0.45 0.43 0.42
rs7574865 STAT4 2q32.3 Intron G/T 0.28 0.31 0.25
rs11650354 TBET    C/T 0.1 0.12 0.15
rs16947078 TBET    A/G 0.12 0.14 0.21
rs11588625 HLX 1q41 Exon (Ala387Gly) T/C 0.14 0.17 0.12
rs11578466 HLX  3’ UTR C/G 0.13 0.15 0.33
aFisher’s exact test for 2×2 comparisons of alleles in the different groups calculated using PLINK.
 Abbreviations: SNP ID, single nucleotide polymorphism identification in rs#; A1, major allele; MAF, minor allele frequency; UTR, 
untranslated region
17q21.32                 Intron
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genes that control the transcription of the IFNγ 
gene, namely, TBET (24), GATA3 (25), STAT1 (26), 
STAT4 (27), and HLX (28), and assessed whether 
their variants were associated with susceptibility/
resistance to TB. We found that the TT genotype 
of TBET is associated with a decreased risk of TB 
in the Colombian population studied, although this 
association was lost after multiple test correction. 
A study with larger numbers of samples will be 
necessary to confirm this association. 
TBET is a member of the T-box family of transcription 
factors that regulate the lineage commitment of T 
helper (Th)-0 lymphocytes toward a predominant 
Th1 phenotype. Different studies have highlighted 
the importance of TBET in the diverse subsets of cells 
that have been implicated in a Th1 immune response, 
such as dendritic cells (45), NK cells (46), and CD8+ 
LT cells (47). The important regulatory role of TBET 
in the course of Mtb infection was established in a 
murine model. Mice that lack TBET due to a targeted 
mutation of this gene are more susceptible to Mtb 
infection than their wild-type (WT) counterparts. 
These mice exhibited a shorter mean survival 
time, less efficient control of bacterial replication, 
and severe lung inflammation following both i.v. 
and respiratory infection (48). The lack of TBET 
expression resulted in a weakening of the systemic 
immune response to M. tuberculosis, evidenced 
by higher bacterial burdens in the lung, liver, and 
spleen. In addition, IFNγ production in response to a 
mycobacterial purified protein derivative (PPD) was 
significantly reduced in T cells isolated from TB lung 
lesions from TBET-/- mice (48).
However, it has been suggested that a disruption 
of the immune response profile balance during 
active TB facilitates an overregulation of the 
effector response, characterized by decreased 
IFNγ production (49), increased IL-4 production 
(50) and the development of regulatory T cells 
(Tregs) that inhibit protective Th1 responses (51). 
A lack of TBET expression generates conditions 
that strongly favor the development of the Th2 
compartment (47). Heritable Th2-associated 
conditions might be caused by genetic variation in 
Th1 cytokine regulation through TBET (52). TBET 
polymorphisms have recently been associated with 
susceptibility to asthma (53,54), diabetes mellitus 
(55), autoimmune diseases (56,57), cancer (58,59), 
and viral infections (60,61). However, to date, no 
polymorphism in TBET has been associated with 
mycobacterial disease, including TB. The present 
report is the first to suggest an association between 
a TBET variant (rs11650354) and tuberculosis in a 
Colombian population. 
The findings of recent genetic studies suggest 
an association between the rs11650354 SNP in 
TBET and systemic sclerosis (56). These authors 
showed that patients with the TT genotype had a 
more prominent Th2 cytokine profile, while patients 
in the wild-type group (CC) had a more prominent 
proinflammatory cytokine profile. They thus 
hypothesized that CD4+ T cells fail to differentiate 
into the Th1 lineage in the presence of the TBET 
TT polymorphism, leading to a Th2-predominant 
environment. This finding supports the potential 
importance of Th1/Th2 cytokine balance in 
autoimmune disease and asthma; this Th1/Th2 
dysregulation could also be expected to affect the 
response to TB and potentially explains our finding 
of the TT genotype as a protective factor against 
TB development.
There is not enough evidence regarding whether 
specific variants of the TBET gene are associated 
with TBET expression/function. Interestingly, 
the levels of TBET messenger RNA (mRNA) in 
peripheral blood cells have been reported to be 
lower in asthma patients than in controls (62), and 
two TBET variants (rs11650354 and rs17699436) 
have been associated with susceptibility to asthma 
(63,64), suggesting that TBET SNPs could affect 
TBET transcription. To better understand the 
immunologic significance of the TBET variant 
rs11650354 in TB, further studies need to be 
undertaken to demonstrate the effects of these 
polymorphisms on mRNA and protein levels and 
TBET function, which in turn could affect IFNγ 
transcription and disturb the immune response.
In summary, this study found evidence of a weak 
association between the TBET TT genotype 
(rs11650354) and resistance to pulmonary TB. 
However, the lack of evidence for this association 
after multiple test correction via permutation casts 
doubts on the robustness of this finding. A further 
replication case-control study will be needed to 
confirm this result. 
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